NCT07101939RecruitingPhase 2
A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
A Two-part, Phase 2a Randomized, Part Parallel-group, Double-blind Placebo-controlled Cross-over Multi-center Study to Evaluate the Effect of Two Dose Levels of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass in Obese Patients During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Source: ClinicalTrials.gov · Last updated 17 Feb 2026
Brief summary (registry, in English)
Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass. The purpose of this study is to investigate the effect of ACM-001.1 (the study drug) on how much muscle is lost when a person takes it with semaglutide (PROACT 1) and how much muscle mass is gained when a person continues taking ACM-001.1 but stops taking semaglutide (PROACT 2).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 20 Jun 2025
- Start date
- 23 Jun 2025
- Primary completion date
- Mar 2027
- Lead sponsor
- Actimed Therapeutics Ltd
- Diseases
- Obesity
- NCT number
- NCT07101939
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 120
- From 23 Jun 2025 to the primary completion date, Mar 2027
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- received a GLP-1RA (including semaglutide),
Other illness
- Type 2 diabetes mellitus who in the preceding 90 days have either:
Lab values
- had a HBA1C over 10.0%.
- Any cardiovascular event within previous 6 months, uncontrolled hypertension, known congestive heart failure, or angina during the past year
- Known severe chronic obstructive pulmonary disease (COPD)
- Concomitant use of beta blockers and patients with contra indications to beta blockers
Other
- had a hypoglycaemic event,
- lost \>5 kg weight,
Who the study is looking for
- Eligible for treatment with semaglutide.
- Have a BMI of ≥30.0 kg/m².
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical hospital center Bezanijska Kosa Coordinator of this site? Confirm its status | Belgrade | Serbia | Recruiting |
| Clinical Hospital Center 'Dr Dragisa Misovic - Dedinje' Coordinator of this site? Confirm its status | Belgrade | Serbia | Recruiting |
| University Clinical Center of Serbia Coordinator of this site? Confirm its status | Belgrade | Serbia | Recruiting |
| University Clinical Center Kragujevac Coordinator of this site? Confirm its status | Kragujevac | Serbia | Recruiting |
| Klinika Za Endocrinologiju, Dijabetes I Bolesti Metabolizma Coordinator of this site? Confirm its status | Niš | Serbia | Recruiting |
| University Clinical Center of Vojvodina Coordinator of this site? Confirm its status | Novi Sad | Serbia | Recruiting |
| Opsta bolnica Pancevo Coordinator of this site? Confirm its status | Pančevo | Serbia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.